воскресенье, 17 июля 2011 г.

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.

In a decree that seems to disc the dominant insight that any form of hormone replacement analysis raises the risk of breast cancer, a untrained look at some old data suggests that estrogen-only hormone cure might protect a unpretentious subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone remedy is actually protective" in women who have a inadequate risk for developing knocker tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver Dapoxetine HCI. With his colleagues, Ragaz took another countenance at information from the Women's Health Initiative (WHI) study, a governmental side that has focused on ways to frustrate bust and colorectal cancer, as well as sincerity blight and fracture risk, in postmenopausal women.

The yoke planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by the world at large experts, divergent studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary pastillas tramacet donde las venden en md. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.

Two groups were division of the suffering - women who had had hysterectomies and took estrogen tout as hormone replacement group therapy and a clique that took estrogen with progestin hormone replacement therapy. The union psychotherapy bad was halted in 2002 after it became assured those women were at increased danger for heart disease and breast cancer.

In the novel look at the estrogen-only group, Ragaz said, "we looked at women who did not have high-risk features". They found that women with no last news of gracious breast disease had a 43 percent reduction soul cancer risk on estrogen; women with no progeny history with a first-degree relevant with breast cancer had a 32 percent peril reduction and women without previous hormone use had a 32 percent reduced risk.

Overall, the 10000-plus participants had a 20 percent reduction in heart of hearts cancer risk, a reduction that approached statistical significance, Ragaz said. After their review, Ragaz said they concluded that using estrogen alone, exceptionally if begun in women less than 60 who don't have a uterus, can staff humble tit cancer risk.

The green review article did not accept drug fellowship funding, Ragaz said. "Women without a uterus should be completely safe and benefit a great deal with estrogen-only use ," he said. Yet, more fact-finding is needed to manage the best treatment regimen, decide who are the ideal candidates and to mould out exactly why the estrogen only reduces jeopardy in some women, he said.

The findings don't in reality include anything new, said Dr Rowan Chlebowski, a WHI investigator who is head of medical oncology/hematology at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The same results, he said, were published back in 2006, when the WHI investigators reported on the estrogen-only arm of the study. "These results have been around for a covet patch of time," he said. But, he added that "you have to be heedful about interpreting subgroups".

To pronounce estrogen is protective, Chlebowski said, is a spot strong. The overall reduction in bosom cancer hazard found mid the 10000 participants - 20 percent - didn't climb to meaning from a statistical object of view, he said. When looked at by subgroups - those with no before-mentioned salutary chest disease, those with no prior HRT use, those with no first-degree connected with breast cancer - the reductions were significant vimax ������. "The dispatch is fair much unchanged by this new review ," he said, adding "I hypothesis it will get people to glance at the data again".

Комментариев нет:

Отправить комментарий